A new clinical trial has shown for the first time that taking high doses of vitamin D could stave off the progression of ...

Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...

Nearly 50% of MS patients report pronounced fatigue, which has a significantly negative impact on their well-being, a Finnish ...

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in ...

A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

In a recent case report published in Frontiers in Immunology, scientists in Canada described how an experimental treatment ...

4 Researchers at the University of Houston recently found that high-efficacy disease-modifying agents decreased the risk of relapse in male patients with multiple sclerosis versus moderate ...

Dr Pavan Bhargava shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights into how new ...

Discover how gut bacteria may influence multiple sclerosis progression and severity. Research reveals specific bacterial ...

Gabryelle “Gabby” Scholfield, a 16-year-old student-athlete at Edmondson Westside High School in Baltimore, who plays center ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to ...